Targeted Therapeutics in Melanoma, Gajewski and Hodi (eds.), is one of a series of publications from Current Clinical Oncology that provides up-to-date information regarding new developments in cancer diagnosis and treatment provided by experts in the respective specialty fields. This volume, with a focus on melanoma, delivers just that, with an impressive list of international contributors. The title may be somewhat misleading, as the book covers mutation-, antiangiogenesis-and immune-targeted therapies equally well.
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It serves as an excellent resource for physicians who, in any specialty, diagnose and treat melanoma patients.
For anyone familiar with melanoma, it is clear that the landscape is rapidly evolving. Melanoma has been long recognized as a disease that, once widely metastatic, is nearly uniformly fatal. Conventional chemotherapy has been disappointing, and despite the recognition that melanoma is one of the more immunogenic of tumors, the effectiveness of previous treatments targeting immune modulation has been meager, at best. In a few short years, however, we have gone from discovery in the laboratory to more effective, although not yet universally curative, treatments. Furthermore, with the application of each new therapy in tandem with on-going basic science investigations, we are gaining more insight into the biology and the mutational drivers of this disease.
Overall, the book is organized in a very logical manner, although it is also formatted such that the reader can easily locate information that is specific and stand-alone in a lication. This can be slightly distracting, but may reflect the current content and timeliness of the publication.
As someone who is familiar with the field, I feel this is an excellent resource and reference for physicians and scientists who want a comprehensive overview of current advances in melanoma therapy. I truly appreciate the opportunity to provide this review. The editors divide this book into three parts: the first addresses advances in the understanding of the biology of melanoma; the second explores signaling molecules as molecular targets; the third grapples with immunotherapeutic approaches in the treatment of melanoma. All of the chapters are written as though they were stand-alone articles, each with an abstract, body, and conclusion.
Of note to dermatopathologists, there has been difficulty in finding correlation with the model of so-called melanoma "progression" as advocated by Clark et al (1984) [1] to the genomics of melanoma. Kashini-Sabet, in chapter 2 (Melanoma Genomics), rightly states that "while this model of melanoma progression was described several years ago and is well understood, prior to the advent of microarray analysis, one would be hard pressed to identify genes whose differential expression corresponded to any of these phases of melanoma progression." This is not at all surprising given that the "progression" hypothesis was dubious from the very beginning, and I take issue that anyone ever understood it.
There is no credible evidence that melanocytic nevi "transform" into melanomas; cells transform, but lesions do not.
What is readily observable is that there are nevi, nevi in conjunction with melanomas, and melanomas. How a melanocyte eventually becomes a melanoma is as much an enigma today as it was when Clark et al wrote their article in 1984.
It is true that there is much new information about certain genes associated with melanomas, but this is not the same as knowing the cause(s) of melanoma. 
